NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.20 -0.20 (-5.88 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$3.20
Today's Range$3.10 - $3.45
52-Week Range$1.55 - $5.75
Volume1.20 million shs
Average Volume481,161 shs
Market Capitalization$161.66 million
P/E Ratio-2.91
Dividend YieldN/A
Beta2.38

About AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals logoAcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500

Debt

Debt-to-Equity Ratio-0.20
Current Ratio4.05
Quick Ratio4.00

Price-To-Earnings

Trailing P/E Ratio-2.91
Forward P/E Ratio-3.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.99 million
Price / Sales20.55
Cash FlowN/A
Price / CashN/A
Book Value($0.91) per share
Price / Book-3.52

Profitability

EPS (Most Recent Fiscal Year)($1.10)
Net Income$-51,500,000.00
Net Margins-909.33%
Return on EquityN/A
Return on Assets-62.92%

Miscellaneous

Employees41
Outstanding Shares51,320,000

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals (NASDAQ:ACRX) issued its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.01. The specialty pharmaceutical company earned $0.34 million during the quarter, compared to the consensus estimate of $0.78 million. View AcelRx Pharmaceuticals' Earnings History.

What price target have analysts set for ACRX?

7 brokers have issued 1 year price objectives for AcelRx Pharmaceuticals' shares. Their forecasts range from $2.00 to $8.00. On average, they anticipate AcelRx Pharmaceuticals' stock price to reach $5.40 in the next twelve months. View Analyst Ratings for AcelRx Pharmaceuticals.

Are investors shorting AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals saw a decrease in short interest in April. As of April 13th, there was short interest totalling 3,186,890 shares, a decrease of 31.0% from the March 30th total of 4,617,564 shares. Based on an average trading volume of 271,624 shares, the days-to-cover ratio is currently 11.7 days. Approximately 7.8% of the shares of the stock are sold short.

Who are some of AcelRx Pharmaceuticals' key competitors?

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:
  • Dr. Pamela Pierce Palmer M.D., Ph.D., Co-Founder, Chief Medical Officer and Director (Age 55)
  • Ms. Jane Wright-Mitchell, Chief Legal Officer (Age 49)
  • Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 55)
  • Mr. Vincent J. Angotti, CEO & Director (Age 50)

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

News stories about ACRX stock have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AcelRx Pharmaceuticals earned a coverage optimism score of 0.21 on Accern's scale. They also assigned media stories about the specialty pharmaceutical company an impact score of 46.65 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Millennium Management LLC (0.45%), Northern Trust Corp (0.18%), A.R.T. Advisors LLC (0.14%) and GSA Capital Partners LLP (0.11%). Company insiders that own AcelRx Pharmaceuticals stock include Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Perceptive Advisors Llc, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.

Which major investors are selling AcelRx Pharmaceuticals stock?

ACRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and A.R.T. Advisors LLC. Company insiders that have sold AcelRx Pharmaceuticals company stock in the last year include Lawrence G Hamel and Life Sciences Maste Perceptive. View Insider Buying and Selling for AcelRx Pharmaceuticals.

Which major investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP and Northern Trust Corp. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $3.20.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $161.66 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]


MarketBeat Community Rating for AcelRx Pharmaceuticals (ACRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  511
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AcelRx Pharmaceuticals (NASDAQ:ACRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for AcelRx Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.40, suggesting that the stock has a possible upside of 68.75%. The high price target for ACRX is $8.00 and the low price target for ACRX is $2.00. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.572.572.572.57
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.40$5.40$6.8333$6.8333
Price Target Upside: 68.75% upside200.00% upside279.63% upside279.63% upside

AcelRx Pharmaceuticals (NASDAQ:ACRX) Consensus Price Target History

Price Target History for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ:ACRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017HC WainwrightReiterated RatingBuy$5.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesReiterated RatingHold$2.00N/AView Rating Details
10/13/2017Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.00N/AView Rating Details
10/13/2017Jefferies GroupDowngradeBuy ➝ HoldN/AView Rating Details
10/12/2017Roth CapitalSet Price TargetBuy$8.00N/AView Rating Details
8/9/2017Stifel NicolausUpgradeHold ➝ BuyHighView Rating Details
8/1/2017CowenReiterated RatingHoldHighView Rating Details
(Data available from 5/25/2016 forward)

Earnings

AcelRx Pharmaceuticals (NASDAQ:ACRX) Earnings History and Estimates Chart

Earnings by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ:ACRX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.24)($0.24)($0.24)
Q2 20181($0.29)($0.29)($0.29)
Q3 20181($0.17)($0.17)($0.17)
Q4 20181($0.30)($0.30)($0.30)

AcelRx Pharmaceuticals (NASDAQ ACRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1($0.24)($0.23)$0.78 million$0.34 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.20)($0.20)$2.90 million$0.74 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.26)($0.28)$2.46 million$1.49 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.28)($0.29)$2.63 million$2.66 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.28)($0.34)$2.36 million$3.11 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.23)($0.21)$3.05 million$6.44 millionViewListenView Earnings Details
11/1/2016Q316($0.23)($0.25)$2.89 million$1.60 millionViewN/AView Earnings Details
7/28/2016Q216($0.22)($0.24)$2.17 million$4.53 millionViewListenView Earnings Details
5/2/2016Q1 2016($0.22)($0.22)$2.05 million$3.03 millionViewN/AView Earnings Details
3/7/2016Q415($0.10)($0.24)$4.97 million$1.73 millionViewListenView Earnings Details
10/29/2015Q315($0.23)$0.11$1.75 million$13.90 millionViewListenView Earnings Details
8/3/2015Q215($0.26)($0.20)$0.30 million$1.92 millionViewListenView Earnings Details
5/4/2015Q115($0.28)($0.27)$0.40 million$0.18 millionViewN/AView Earnings Details
3/9/2015Q4 2014($0.33)($0.32)$0.23 millionViewN/AView Earnings Details
11/10/2014Q4 2014($0.33)($0.32)$4.95 million$4.83 millionViewN/AView Earnings Details
8/11/2014Q214($0.27)($0.34)$0.20 million$0.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.23)($0.22)$0.28 million$0.10 millionViewN/AView Earnings Details
3/3/2014Q413($0.17)($0.18)$4.93 million$27.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.19)($0.26)$0.40 million$0.55 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.22)($0.22)$1.73 million$0.4070 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.26)($0.34)$0.68 million$0.94 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.39)($0.41)ViewN/AView Earnings Details
11/6/2012Q312($0.38)($0.38)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.39)($0.35)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.35)($0.36)ViewN/AView Earnings Details
3/20/2012Q4 2011($0.39)($0.33)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.34)($0.30)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.32)($0.25)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.22)($0.30)ViewN/AView Earnings Details
3/24/2011Q4 2010($5.23)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AcelRx Pharmaceuticals (NASDAQ:ACRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.50%
Institutional Ownership Percentage: 8.94%
Insider Trading History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Institutional Ownership by Quarter for AcelRx Pharmaceuticals (NASDAQ:ACRX)

AcelRx Pharmaceuticals (NASDAQ ACRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/14/2017Mark G EdwardsDirectorBuy30,000$1.90$57,000.00150,000View SEC Filing  
11/13/2017Raffi AsadorianCFOBuy5,000$1.94$9,700.0012,000View SEC Filing  
10/2/2017Lawrence G HamelInsiderSell10,161$5.29$53,751.6916,379View SEC Filing  
9/11/2017Raffi AsadorianCFOBuy7,000$3.24$22,680.007,000View SEC Filing  
8/24/2017Mark G EdwardsDirectorBuy5,000$3.02$15,100.00115,200View SEC Filing  
8/24/2017Vincent J AngottiCEOBuy15,000$3.00$45,000.0015,000View SEC Filing  
8/22/2017Pamela P. PalmerInsiderBuy10,000$2.95$29,500.00View SEC Filing  
6/19/2017Life Sciences Maste PerceptiveMajor ShareholderSell875,000$2.40$2,100,000.00View SEC Filing  
9/29/2016Perceptive Advisors LlcMajor ShareholderSell216,500$3.92$848,680.00View SEC Filing  
9/15/2016Perceptive Advisors LlcMajor ShareholderSell392,850$3.70$1,453,545.00View SEC Filing  
5/13/2016Howard B RosenCEOBuy10,206$3.26$33,271.5650,000View SEC Filing  
5/12/2016Mark G EdwardsDirectorBuy15,000$3.15$47,250.00105,000View SEC Filing  
11/18/2015Perceptive Advisors LlcMajor ShareholderSell176,200$5.35$942,670.00View SEC Filing  
11/6/2015Perceptive Advisors LlcMajor ShareholderSell92,100$4.59$422,739.00View SEC Filing  
9/9/2015Perceptive Advisors LlcMajor ShareholderSell310,000$4.18$1,295,800.00View SEC Filing  
5/7/2015Mark G EdwardsDirectorBuy40,000$3.13$125,200.00View SEC Filing  
3/10/2014Mark WanDirectorSell1,000,000$12.35$12,350,000.00View SEC Filing  
11/7/2013Perceptive Advisors Llcmajor shareholderBuy200,000$6.51$1,302,000.00View SEC Filing  
11/4/2013Perceptive Advisors Llcmajor shareholderBuy155,000$6.87$1,064,850.00View SEC Filing  
11/1/2013Perceptive Advisors LlcMajor ShareholderBuy360,660$6.91$2,492,160.60View SEC Filing  
9/20/2013Guy NohraDirectorSell158,153$10.59$1,674,840.27View SEC Filing  
9/18/2013Guy NohraDirectorSell128,780$10.42$1,341,887.60View SEC Filing  
7/23/2013Perceptive Advisors LlcMajor ShareholderBuy850,000$11.65$9,902,500.00View SEC Filing  
6/6/2013Mark G EdwardsDirectorBuy10,000$8.10$81,000.00View SEC Filing  
5/28/2013Adrian AdamsDirectorBuy75,000$8.19$614,250.00View SEC Filing  
12/7/2012Mark A WanDirectorBuy2,416,918$3.31$7,999,998.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AcelRx Pharmaceuticals (NASDAQ ACRX) News Headlines

Source:
DateHeadline
AcelRx Pharma (ACRX) Says FDA Accepts NDA for DSUVIA; 11/3 PDUFAAcelRx Pharma (ACRX) Says FDA Accepts NDA for DSUVIA; 11/3 PDUFA
www.streetinsider.com - May 25 at 8:18 AM
Leerink-led investors acquire Three Arch stake in AcelRx; shares up 7%Leerink-led investors acquire Three Arch stake in AcelRx; shares up 7%
seekingalpha.com - May 24 at 8:19 AM
FDA accepts AcelRxs Dsuvia NDA, shares up 13% premarketFDA accepts AcelRx's Dsuvia NDA, shares up 13% premarket
seekingalpha.com - May 24 at 8:19 AM
AcelRx announces FDA acceptance of NDA for DSUVIAAcelRx announces FDA acceptance of NDA for DSUVIA
finance.yahoo.com - May 24 at 8:19 AM
 Brokerages Anticipate AcelRx Pharmaceuticals (ACRX) Will Announce Quarterly Sales of $980,000.00 Brokerages Anticipate AcelRx Pharmaceuticals (ACRX) Will Announce Quarterly Sales of $980,000.00
www.americanbankingnews.com - May 24 at 2:32 AM
BRIEF-Three Archs Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry ...BRIEF-Three Arch's Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry ...
www.reuters.com - May 23 at 8:18 AM
Three Archs shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and ...Three Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and ...
www.prnewswire.com - May 23 at 8:18 AM
Three Archs shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry VenturesThree Arch's shares of AcelRx common stock acquired in a private transaction led by Leerink Revelation Partners and Industry Ventures
finance.yahoo.com - May 23 at 8:18 AM
-$0.22 EPS Expected for AcelRx Pharmaceuticals (ACRX) This Quarter-$0.22 EPS Expected for AcelRx Pharmaceuticals (ACRX) This Quarter
www.americanbankingnews.com - May 22 at 5:14 PM
AcelRx Pharmaceuticals to Present at Jefferies 2018 Global Healthcare ConferenceAcelRx Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - May 22 at 5:09 PM
Why You Need To Look At This Factor Before Buying AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)Why You Need To Look At This Factor Before Buying AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
finance.yahoo.com - May 18 at 8:39 AM
Zacks Investment Research Upgrades AcelRx Pharmaceuticals (ACRX) to BuyZacks Investment Research Upgrades AcelRx Pharmaceuticals (ACRX) to Buy
www.americanbankingnews.com - May 15 at 4:26 PM
Blog Exposure - AcelRx Pharma Resubmitted New Drug Application for DSUVIA with FDABlog Exposure - AcelRx Pharma Resubmitted New Drug Application for DSUVIA with FDA
finance.yahoo.com - May 11 at 8:26 AM
AcelRx Pharmaceuticals (ACRX) Announces  Earnings Results, Beats Estimates By $0.01 EPSAcelRx Pharmaceuticals (ACRX) Announces Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 10 at 6:12 PM
AcelRx Pharma (ACRX) Resubmits NDA for DSUVIAAcelRx Pharma (ACRX) Resubmits NDA for DSUVIA
www.streetinsider.com - May 10 at 8:23 AM
AcelRx Pharmaceuticals (ACRX) CEO Vince Angotti on Q1 2018 Results - Earnings Call TranscriptAcelRx Pharmaceuticals' (ACRX) CEO Vince Angotti on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:23 AM
Edited Transcript of ACRX earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of ACRX earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:23 AM
AcelRx refiles U.S. marketing application for Dsuvia, action date Q4; shares up 10% premarketAcelRx refiles U.S. marketing application for Dsuvia, action date Q4; shares up 10% premarket
seekingalpha.com - May 9 at 5:35 PM
Want To Invest In AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)? Here’s How It Performed LatelyWant To Invest In AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)? Here’s How It Performed Lately
finance.yahoo.com - May 9 at 5:35 PM
AcelRx Pharmaceuticals: 1Q Earnings SnapshotAcelRx Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:35 PM
AcelRx Pharmaceuticals Reports First Quarter 2018 Financial ResultsAcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 5:35 PM
AcelRx resubmits New Drug Application for DSUVIA™AcelRx resubmits New Drug Application for DSUVIA™
finance.yahoo.com - May 9 at 8:18 AM
Stocks Under Scanner in the Medical Equipment Space – Accuray and Two more Stock Research Monitor: ACRX, and CHFSStocks Under Scanner in the Medical Equipment Space – Accuray and Two more Stock Research Monitor: ACRX, and CHFS
finance.yahoo.com - May 9 at 8:18 AM
AcelRx Pharmaceuticals (ACRX) Expected to Announce Quarterly Sales of $780,000.00AcelRx Pharmaceuticals (ACRX) Expected to Announce Quarterly Sales of $780,000.00
www.americanbankingnews.com - May 7 at 4:38 AM
AcelRx Pharmaceuticals (ACRX) Given Average Rating of "Hold" by AnalystsAcelRx Pharmaceuticals (ACRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 6 at 7:39 PM
AcelRx Pharmaceuticals (ACRX) Expected to Announce Earnings of -$0.24 Per ShareAcelRx Pharmaceuticals (ACRX) Expected to Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - May 5 at 9:39 AM
ValuEngine Upgrades AcelRx Pharmaceuticals (ACRX) to "Sell"ValuEngine Upgrades AcelRx Pharmaceuticals (ACRX) to "Sell"
www.americanbankingnews.com - May 4 at 3:35 PM
AcelRx Pharmaceuticals (ACRX) to Release Quarterly Earnings on WednesdayAcelRx Pharmaceuticals (ACRX) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 9:42 PM
PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018
www.prnewswire.com - May 2 at 8:20 AM
AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia ...AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia ...
www.prnewswire.com - May 2 at 8:20 AM
AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia SystemsAcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems
finance.yahoo.com - April 30 at 8:23 AM
European advisory group backs AcelRxs pain med Dzuveo; shares up 11%European advisory group backs AcelRx's pain med Dzuveo; shares up 11%
seekingalpha.com - April 27 at 5:15 PM
BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In ...BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In ...
www.reuters.com - April 27 at 8:29 AM
AcelRx Pharma (ACRX) Receives Positive CHMP Opinion for DZUVEO for Management of PainAcelRx Pharma (ACRX) Receives Positive CHMP Opinion for DZUVEO for Management of Pain
www.streetinsider.com - April 27 at 8:29 AM
AcelRx receives positive CHMP opinion for DZUVEO™ for management of acute moderate to severe pain in medically monitored settingsAcelRx receives positive CHMP opinion for DZUVEO™ for management of acute moderate to severe pain in medically monitored settings
finance.yahoo.com - April 27 at 8:29 AM
Short Interest in AcelRx Pharmaceuticals (ACRX) Declines By 31.0%Short Interest in AcelRx Pharmaceuticals (ACRX) Declines By 31.0%
www.americanbankingnews.com - April 27 at 1:24 AM
AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018
www.prnewswire.com - April 25 at 4:46 PM
$780,000.00 in Sales Expected for AcelRx Pharmaceuticals (ACRX) This Quarter$780,000.00 in Sales Expected for AcelRx Pharmaceuticals (ACRX) This Quarter
www.americanbankingnews.com - April 20 at 4:28 AM
-$0.24 Earnings Per Share Expected for AcelRx Pharmaceuticals (ACRX) This Quarter-$0.24 Earnings Per Share Expected for AcelRx Pharmaceuticals (ACRX) This Quarter
www.americanbankingnews.com - April 18 at 8:32 AM
Pharmacokinetics of AcelRx Pharmas sublingual sufentanil supports effectiveness in monitored setting; shares up 4% premarketPharmacokinetics of AcelRx Pharma's sublingual sufentanil supports effectiveness in monitored setting; shares up 4% premarket
seekingalpha.com - April 18 at 8:16 AM
AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored SettingAcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting
finance.yahoo.com - April 18 at 8:16 AM
Blog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIABlog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIA
finance.yahoo.com - April 18 at 8:16 AM
AcelRx Pharmaceuticals (ACRX) Upgraded to "Hold" at ValuEngineAcelRx Pharmaceuticals (ACRX) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 16 at 7:34 PM
AcelRx completes the human factors study for DSUVIA; plans to resubmit NDA in Q2AcelRx completes the human factors study for DSUVIA; plans to resubmit NDA in Q2
seekingalpha.com - April 16 at 8:15 AM
AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018
finance.yahoo.com - April 16 at 8:15 AM
AcelRx Pharmaceuticals (ACRX) Stock Rating Lowered by ValuEngineAcelRx Pharmaceuticals (ACRX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 14 at 2:30 PM
AcelRx Pharmaceuticals (ACRX) Stock Rating Reaffirmed by CowenAcelRx Pharmaceuticals (ACRX) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 14 at 11:48 AM
AcelRx Pharmaceuticals (ACRX) Lifted to "Buy" at Stifel NicolausAcelRx Pharmaceuticals (ACRX) Lifted to "Buy" at Stifel Nicolaus
www.americanbankingnews.com - April 12 at 12:29 AM
AcelRx Pharmaceuticals (ACRX) Receives Consensus Rating of "Hold" from AnalystsAcelRx Pharmaceuticals (ACRX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 11 at 5:43 PM
AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in EuropeAcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe
finance.yahoo.com - April 11 at 5:32 PM

SEC Filings

AcelRx Pharmaceuticals (NASDAQ:ACRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AcelRx Pharmaceuticals (NASDAQ:ACRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AcelRx Pharmaceuticals (NASDAQ ACRX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.